HK1207307A1 - 放射性药物络合物 - Google Patents
放射性药物络合物 Download PDFInfo
- Publication number
- HK1207307A1 HK1207307A1 HK15108017.5A HK15108017A HK1207307A1 HK 1207307 A1 HK1207307 A1 HK 1207307A1 HK 15108017 A HK15108017 A HK 15108017A HK 1207307 A1 HK1207307 A1 HK 1207307A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- complex
- moiety
- moieties
- tissue
- targeting moiety
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
- A61K51/0478—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group complexes from non-cyclic ligands, e.g. EDTA, MAG3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Hematology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB201208309A GB201208309D0 (en) | 2012-05-11 | 2012-05-11 | Complexes |
| GB1208309.3 | 2012-05-11 | ||
| PCT/EP2013/059840 WO2013167755A1 (en) | 2012-05-11 | 2013-05-13 | Radio-pharmaceutical complexes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1207307A1 true HK1207307A1 (zh) | 2016-01-29 |
Family
ID=46458687
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK15107609.1A HK1206982A1 (en) | 2012-05-11 | 2013-05-13 | Radio-pharmaceutical complexes |
| HK15107608.2A HK1206981A1 (en) | 2012-05-11 | 2013-05-13 | Radio-pharmaceutical complexes |
| HK15108017.5A HK1207307A1 (zh) | 2012-05-11 | 2013-05-13 | 放射性药物络合物 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK15107609.1A HK1206982A1 (en) | 2012-05-11 | 2013-05-13 | Radio-pharmaceutical complexes |
| HK15107608.2A HK1206981A1 (en) | 2012-05-11 | 2013-05-13 | Radio-pharmaceutical complexes |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US20150104385A1 (enExample) |
| EP (3) | EP2846843A1 (enExample) |
| JP (3) | JP6211066B2 (enExample) |
| KR (3) | KR20150092702A (enExample) |
| CN (3) | CN104619355A (enExample) |
| CA (3) | CA2873143A1 (enExample) |
| GB (1) | GB201208309D0 (enExample) |
| HK (3) | HK1206982A1 (enExample) |
| WO (3) | WO2013167754A1 (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008008797A2 (en) | 2006-07-10 | 2008-01-17 | The Regents Of The University Of California | Luminescent 1-hydroxy-2-pyridinone chelates of lanthanides |
| EP2816038B8 (en) | 2009-08-24 | 2019-12-25 | Lumiphore, Inc. | Hopo chelators |
| GB201002508D0 (en) | 2010-02-12 | 2010-03-31 | Algeta As | Product |
| GB201208309D0 (en) | 2012-05-11 | 2012-06-27 | Algeta As | Complexes |
| US11453652B2 (en) | 2013-03-15 | 2022-09-27 | Lumiphore, Inc. | Di-macrocycles |
| MA41176A (fr) * | 2014-12-17 | 2017-10-24 | Bayer As | Complexes radio-pharmaceutiques |
| US10821195B2 (en) * | 2015-09-10 | 2020-11-03 | Memorial Sloan Kettering Cancer Center | Compositions for therapeutics, targeted PET imaging and methods of their use |
| GB201600158D0 (en) * | 2016-01-05 | 2016-02-17 | Bayer As | Purification method |
| GB201600154D0 (en) * | 2016-01-05 | 2016-02-17 | Bayer As | Isotope preparation method |
| BR112018069485A2 (pt) * | 2016-03-24 | 2019-07-30 | Bayer As | complexos radiofarmacêuticos |
| MA45225A (fr) | 2016-06-10 | 2019-04-17 | Bayer As | Complexes radiopharmaceutiques |
| CA3054248A1 (en) * | 2017-02-24 | 2018-08-30 | Bayer As | Combination therapy comprising a radiopharmaceutical and a dna-repair inhibitor |
| MX2020009472A (es) * | 2018-03-14 | 2020-12-07 | Us Health | Receptores de antigenos quimericos anti-cd33 y sus usos. |
| EP3843743A1 (en) | 2018-08-28 | 2021-07-07 | Bayer AS | Combination of pi3k-inhibitors and targeted thorium conjugates |
| CN113056288A (zh) * | 2018-11-20 | 2021-06-29 | 康奈尔大学 | 放射性核素的大环配合物及其在癌症的放射治疗中的应用 |
| USD885822S1 (en) | 2018-12-14 | 2020-06-02 | Whirlpool Corporation | Food grinder |
| US20220125960A1 (en) | 2019-02-21 | 2022-04-28 | Bayer Aktiengesellschaft | Combination of pd-1/pd-l1 inhibitors and targeted thorium conjugates |
| EP3927339A1 (en) | 2019-02-22 | 2021-12-29 | Bayer Aktiengesellschaft | Combination of ar antagonists and targeted thorium conjugates |
| WO2021013978A1 (en) | 2019-07-25 | 2021-01-28 | Bayer As | Targeted radiopharmaceuticals for the diagnosis and treatment of prostate cancer |
| EP4087621A4 (en) * | 2020-01-10 | 2024-01-17 | Fusion Pharmaceuticals Inc. | MACROCYCLIC CHELATES AND USES THEREOF |
| CN115916731A (zh) * | 2020-01-23 | 2023-04-04 | 瑞德兰有限责任公司 | 用于制备定制的放射性同位素溶液的系统和方法 |
| EP4251179A4 (en) * | 2020-11-30 | 2024-11-20 | Simcere Innovation, Inc. | Universal chimeric antigen receptor-expressing immune cells for allogeneic cell therapy |
| CA3208778A1 (en) | 2021-01-22 | 2022-07-28 | Bayer Aktiengesellschaft | Lrrc15 antibodies and conjugates thereof |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4698431A (en) * | 1985-11-12 | 1987-10-06 | The United States Of America As Represented By The United States Department Of Energy | Hydroxypyridonate chelating agents |
| US5624901A (en) * | 1994-04-15 | 1997-04-29 | The Regents Of The University Of California | 3-hydroxy-2(1H)-pyridinone chelating agents |
| US8383081B2 (en) * | 1999-05-10 | 2013-02-26 | Immunomedics, Inc. | Anti-CD74 immunoconjugates and methods of use |
| NO312708B1 (no) | 2000-02-21 | 2002-06-24 | Anticancer Therapeutic Inv Sa | Radioaktive liposomer til terapi |
| NO313180B1 (no) | 2000-07-04 | 2002-08-26 | Anticancer Therapeutic Inv Sa | Bensökende alfapartikkel emitterende radiofarmasöytika |
| GB0308731D0 (en) | 2003-04-15 | 2003-05-21 | Anticancer Therapeutic Inv Sa | Method of radiotherapy |
| CA2570191C (en) | 2004-06-25 | 2015-04-28 | The European Community, Represented By The European Commission | Radionuclides for medical use |
| US7794691B2 (en) * | 2004-06-25 | 2010-09-14 | The European Community, Represented By The European Commission | Radionuclides for medical use |
| JP5352460B2 (ja) | 2006-08-15 | 2013-11-27 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | ルミネッセント大環状ランタニド錯体 |
| EP2104662A2 (en) * | 2007-01-11 | 2009-09-30 | GE Healthcare AS | Chelating agents |
| WO2011011592A1 (en) * | 2009-07-22 | 2011-01-27 | Actinium Pharmaceuticals Inc. | Methods for generating radioimmunoconjugates |
| EP3263562A1 (en) * | 2009-12-24 | 2018-01-03 | Lumiphore, Inc. | Radiopharmaceutical complexes |
| ES2496991T3 (es) * | 2010-02-12 | 2014-09-22 | Evonik Degussa Gmbh | Composición cosmética que contiene éster parcial de poliglicerol |
| GB201002508D0 (en) | 2010-02-12 | 2010-03-31 | Algeta As | Product |
| GB201208309D0 (en) | 2012-05-11 | 2012-06-27 | Algeta As | Complexes |
-
2012
- 2012-05-11 GB GB201208309A patent/GB201208309D0/en not_active Ceased
-
2013
- 2013-05-13 WO PCT/EP2013/059839 patent/WO2013167754A1/en not_active Ceased
- 2013-05-13 JP JP2015510838A patent/JP6211066B2/ja not_active Expired - Fee Related
- 2013-05-13 HK HK15107609.1A patent/HK1206982A1/xx unknown
- 2013-05-13 US US14/400,020 patent/US20150104385A1/en not_active Abandoned
- 2013-05-13 KR KR1020147034743A patent/KR20150092702A/ko not_active Withdrawn
- 2013-05-13 EP EP13721975.4A patent/EP2846843A1/en not_active Withdrawn
- 2013-05-13 CN CN201380036807.4A patent/CN104619355A/zh active Pending
- 2013-05-13 WO PCT/EP2013/059840 patent/WO2013167755A1/en not_active Ceased
- 2013-05-13 CA CA 2873143 patent/CA2873143A1/en not_active Abandoned
- 2013-05-13 JP JP2015510840A patent/JP6219372B2/ja not_active Expired - Fee Related
- 2013-05-13 EP EP13721784.0A patent/EP2846842A1/en not_active Withdrawn
- 2013-05-13 WO PCT/EP2013/059841 patent/WO2013167756A1/en not_active Ceased
- 2013-05-13 CA CA2873144A patent/CA2873144C/en not_active Expired - Fee Related
- 2013-05-13 CN CN201380036905.8A patent/CN104540530A/zh active Pending
- 2013-05-13 CA CA2873142A patent/CA2873142A1/en not_active Abandoned
- 2013-05-13 HK HK15107608.2A patent/HK1206981A1/xx unknown
- 2013-05-13 US US14/400,026 patent/US9827336B2/en active Active
- 2013-05-13 EP EP13725586.5A patent/EP2846844B1/en active Active
- 2013-05-13 JP JP2015510839A patent/JP2015523326A/ja active Pending
- 2013-05-13 KR KR1020147034742A patent/KR20150092701A/ko not_active Withdrawn
- 2013-05-13 US US14/400,031 patent/US20150147272A1/en not_active Abandoned
- 2013-05-13 HK HK15108017.5A patent/HK1207307A1/xx unknown
- 2013-05-13 CN CN201380035189.1A patent/CN104602716A/zh active Pending
- 2013-05-13 KR KR1020147034741A patent/KR20150092700A/ko not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| KR20150092702A (ko) | 2015-08-13 |
| US20150104385A1 (en) | 2015-04-16 |
| EP2846844A1 (en) | 2015-03-18 |
| WO2013167755A1 (en) | 2013-11-14 |
| JP6219372B2 (ja) | 2017-10-25 |
| US20150110817A1 (en) | 2015-04-23 |
| CN104540530A (zh) | 2015-04-22 |
| KR20150092700A (ko) | 2015-08-13 |
| HK1206982A1 (en) | 2016-01-22 |
| GB201208309D0 (en) | 2012-06-27 |
| JP6211066B2 (ja) | 2017-10-11 |
| CN104619355A (zh) | 2015-05-13 |
| HK1206981A1 (en) | 2016-01-22 |
| US20150147272A1 (en) | 2015-05-28 |
| JP2015517482A (ja) | 2015-06-22 |
| CA2873143A1 (en) | 2013-11-14 |
| CN104602716A (zh) | 2015-05-06 |
| KR20150092701A (ko) | 2015-08-13 |
| CA2873144A1 (en) | 2013-11-14 |
| CA2873144C (en) | 2021-03-16 |
| JP2015517483A (ja) | 2015-06-22 |
| US9827336B2 (en) | 2017-11-28 |
| WO2013167754A1 (en) | 2013-11-14 |
| WO2013167756A1 (en) | 2013-11-14 |
| CA2873142A1 (en) | 2013-11-14 |
| EP2846842A1 (en) | 2015-03-18 |
| JP2015523326A (ja) | 2015-08-13 |
| EP2846843A1 (en) | 2015-03-18 |
| EP2846844B1 (en) | 2020-04-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2846844B1 (en) | Radio-pharmaceutical complexes | |
| US10682430B2 (en) | Alpha-emitting complexes | |
| US20170340759A1 (en) | Radio-pharmaceutical complexes |